QurieGen

QurieGen (est. April 2022) aspires to revolutionize drug discovery. This biotech startup leverages a proprietary method of mapping cellular responses to drug stimuli. Uniquely, this disruptive technology reveals the full picture of the signaling pathways, replacing many different, mutually incompatible analytical tools that at best provide an incomplete picture of the cell response to drug perturbations. The QurieGen R&D team will build a unique AI platform to predict cellular responses to drug candidate molecules, enabling data-driven discovery. Currently, we are raising seed investment to accelerate our operations. Please contact us if you are interested in investing in QurieGen.